Please login to the form below

tralokinumab

This page shows the latest tralokinumab news and features for those working in and with pharma, biotech and healthcare.

MorphoSys drops Novartis-partnered drug in eczema after phase 2 miss

There are a number of drugs coming through the collective industry pipeline as well, including IL-13 inhibitors from Dermira (lebrikizumab) and Leo Pharma (tralokinumab) and oral JAK inhibitors such as

Latest news

AZ’s Fasenra hit by COPD trial failure

IL-13 inhibitor tralokinumab has been abandoned after three failed late-stage trials, however, while AZ also has an Amgen-partnered thymic stromal lymphopoietin (TSLP) targeting antibody - tezepelumab - in phase III
AZ gets EMA green light for severe asthma drug Fasenra

Prospects for IL-13 inhibitor tralokinumab look terminal after three failed late-stage trials, however, and AZ also has an Amgen-partnered thymic stromal lymphopoietin (TSLP) targeting antibody - tezepelumab - in phase
AZ prices severe asthma drug Fasenra below competition

Prospects for IL-13 inhibitor tralokinumab look rocky after two failed late-stage trials, elevating the importance of Fasenra in those plans.
AZ severe asthma drug benralizumab backed by CHMP

Benralizumab has assumed much greater importance for the company since IL-13 inhibitor tralokinumab - another severe asthma candidate - failed two phase III trials.
Setback for AZ as tralokinumab flunks asthma trial

Puts more pressure on AZ’s benralizumab to reach its potential. AstraZeneca’s hopes of bringing severe asthma candidate tralokinumab to market look rocky after it failed two phase III trials. ... Tralokinumab is an inhibitor of interleukin-13 (IL-13),

More from news
Approximately 4 fully matching, plus 17 partially matching documents found.

Latest Intelligence

Leo has its eyes on the prize

Its landmark partnership with AstraZeneca and the launch of Kyntheum, the fully-human monoclonal antibody targeting psoriasis, and the phase III hope of tralokinumab for atopic dermatitis are part of an
2016: The year when deal-makers took stock?

Out-partnering deals included the $1.1bn licence to LEO for tralokinumab in skin diseases and the $1bn divestment to Pfizer of its late-stage small molecule anti-infective business.
Deal Watch July 2016

AstraZeneca is developing tralokinumab for severe asthma, where it is in phase III development, and has recently completed a phase IIb study in patients with atopic dermatitis. ... Acquisition. 1, 530. AstraZeneca/ Leo Pharma. Tralokinumab (anti-IL-13)

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Experienced medical editor: Competitive salary and bonus scheme

Digital Associate Director - Medcomms: £65000 - £80000 per annum

Senior Medical Writer, MedComms Agency: Salary TBC

Account Director: £Competitive Salary

Account director: Competitive salary and bonus scheme

Senior External Communications Lead: £Competitive Salary

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Senior Medical Writer or Lead Medical Writer: £Competitive Salary

Account Director, Healthcare Communications: Salary TBC

Brand Manager - Medium Global Pharma Company: £Competitive Financial Package

Account Manager: £Competitive Salary

Account Manager (PR): Great Benefits

Scientific Director: £60000 - £85000 per annum, Benefits: Bonus, pension, subsidised gym and much more

Publications director: Competitive salary and bonus scheme

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Account Director, Medical Education: Salary TBC

Group Director of Medical Affairs and Scientific Strategy, Medic...: Substantial six figure package

Subscribe to our email news alerts

PMHub

Add my company

Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

Novo Nordisk awakens its ‘Sleeping Beauty’: Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
How will the Tories’ historic win shape the NHS?: Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
CSR 'Christmas Spirit' 2019: OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...